Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:DNLI NASDAQ:ROIV NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$19.88-2.4%$18.96$13.52▼$35.25$2.06B2.142.84 million shs2.15 million shsDNLIDenali Therapeutics$14.64-4.7%$14.60$10.57▼$33.33$2.25B1.231.96 million shs1.67 million shsROIVRoivant Sciences$13.77+2.2%$11.73$8.73▼$13.82$9.21B1.155.46 million shs13.12 million shsRVMDRevolution Medicines$40.45-1.2%$37.56$29.17▼$62.40$7.65B1.121.81 million shs1.79 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-2.36%+5.97%+15.78%+13.99%-15.94%DNLIDenali Therapeutics-4.69%-4.38%+5.23%-1.94%-44.42%ROIVRoivant Sciences+2.15%+9.37%+23.28%+20.05%+12.96%RVMDRevolution Medicines-1.20%+1.71%+16.57%-1.61%-2.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$19.88-2.4%$18.96$13.52▼$35.25$2.06B2.142.84 million shs2.15 million shsDNLIDenali Therapeutics$14.64-4.7%$14.60$10.57▼$33.33$2.25B1.231.96 million shs1.67 million shsROIVRoivant Sciences$13.77+2.2%$11.73$8.73▼$13.82$9.21B1.155.46 million shs13.12 million shsRVMDRevolution Medicines$40.45-1.2%$37.56$29.17▼$62.40$7.65B1.121.81 million shs1.79 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-2.36%+5.97%+15.78%+13.99%-15.94%DNLIDenali Therapeutics-4.69%-4.38%+5.23%-1.94%-44.42%ROIVRoivant Sciences+2.15%+9.37%+23.28%+20.05%+12.96%RVMDRevolution Medicines-1.20%+1.71%+16.57%-1.61%-2.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.08Buy$46.40133.40% UpsideDNLIDenali Therapeutics 3.12Buy$33.50128.83% UpsideROIVRoivant Sciences 3.50Strong Buy$17.6728.30% UpsideRVMDRevolution Medicines 3.00Buy$72.0078.00% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, BEAM, ROIV, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/5/2025RVMDRevolution MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$99.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$75.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$67.008/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$57.00 ➝ $56.008/6/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$25.00 ➝ $21.007/28/2025DNLIDenali TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/21/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M31.66N/AN/A$8.86 per share2.24DNLIDenali Therapeutics$330.53M6.48N/AN/A$8.53 per share1.72ROIVRoivant Sciences$29.05M323.69N/AN/A$7.45 per share1.85RVMDRevolution Medicines$11.58M652.96N/AN/A$13.47 per share3.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest DNLI, BEAM, ROIV, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A6.756.75DNLIDenali Therapeutics0.0110.2710.27ROIVRoivant SciencesN/A40.5440.54RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%DNLIDenali Therapeutics92.92%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%DNLIDenali Therapeutics12.50%ROIVRoivant Sciences10.80%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableDNLI, BEAM, ROIV, and RVMD HeadlinesRecent News About These CompaniesRevolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic ...September 10 at 5:45 PM | finance.yahoo.comRevolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal AdenocarcinomaSeptember 10 at 4:02 PM | globenewswire.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from BrokeragesSeptember 10 at 2:37 AM | marketbeat.comCinctive Capital Management LP Reduces Stock Position in Revolution Medicines, Inc. $RVMDSeptember 8 at 5:47 AM | marketbeat.comAdage Capital Partners GP L.L.C. Sells 256,000 Shares of Revolution Medicines, Inc. $RVMDSeptember 8 at 4:57 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Truist FinancialSeptember 8 at 2:05 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Analysts at Truist FinancialSeptember 7, 2025 | marketbeat.comGranahan Investment Management LLC Purchases 7,322 Shares of Revolution Medicines, Inc. $RVMDSeptember 7, 2025 | marketbeat.com59,214 Shares in Revolution Medicines, Inc. $RVMD Purchased by Trexquant Investment LPSeptember 7, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD is Checkpoint Capital L.P.'s 3rd Largest PositionSeptember 6, 2025 | marketbeat.comRevolution Medicines initiated with a Buy at TruistSeptember 6, 2025 | msn.comTruist Securities Initiates Coverage of Revolution Medicines (RVMD) with Buy RecommendationSeptember 6, 2025 | msn.comJump Financial LLC Makes New $287,000 Investment in Revolution Medicines, Inc. $RVMDSeptember 6, 2025 | marketbeat.comJack Anders Sells 4,762 Shares of Revolution Medicines (NASDAQ:RVMD) StockSeptember 5, 2025 | insidertrades.comBVF Inc. IL Purchases 801,205 Shares of Revolution Medicines, Inc. $RVMDSeptember 5, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Stock Price Up 5.2% - Here's WhySeptember 4, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Stock Holdings Lifted by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comParadigm Biocapital Advisors LP Sells 375,000 Shares of Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Stock Holdings Increased by Magnetar Financial LLCSeptember 2, 2025 | marketbeat.comLandscape Capital Management L.L.C. Buys Shares of 17,213 Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comB. Metzler seel. Sohn & Co. AG Acquires 8,622 Shares of Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, BEAM, ROIV, and RVMD Company DescriptionsBeam Therapeutics NASDAQ:BEAM$19.88 -0.48 (-2.36%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$19.97 +0.09 (+0.45%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$14.64 -0.72 (-4.69%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$14.68 +0.04 (+0.27%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Roivant Sciences NASDAQ:ROIV$13.77 +0.29 (+2.15%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$13.80 +0.03 (+0.22%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$40.45 -0.49 (-1.20%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$43.66 +3.21 (+7.94%) As of 06:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
